Loading...
 

Volume 35, Issue 1, March 2024



Sign in to download the Issue in PDF format.

Back to the list
Mediterr J Rheumatol 2021;32(1):31-8
Article Links
Spectrum of Myelitis in Systemic Lupus Erythematosus: Experience from a Single Tertiary Care Centre over 25 Years
Pankti Mehta, Latika Gupta, Hafis Muhammed, Durga P. Misra, Able Lawrence, Vikas Agarwal, Amita Aggarwal, Ramnath Misra
Authors Information

Department of Clinical Immunology and Rheumatology, SGPGIMS, Lucknow, India

Latika Gupta, Pankti Mehta, Hafis Muhammed, Durga P. Misra, Able Lawrence, Vikas Agarwal, Amita Aggarwal,  Ramnath Misra 

Keywords: SLE, lupus, myelitis, demyelinating syndromes, neuromyelitis optica spectrum disorders, rituximab, neuropsychiatric lupus
References
  1. Liang MH, Corzillius M, Bae SC, Lew RA, Fortin PR, Gordon C, et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum (Hoboken, NJ) 1999 Apr 1;42(4):599-608.
  2. Bertsias G, Cervera R, Boumpas DT. Systemic Lupus 20 Erythematosus: Pathogenesis and Clinical Features. Systemic Lupus Erythematosus. EULAR Textbook on Rheumatic Diseases, 5, 2012;476-505.
  3. Piga M, Chessa E, Peltz MT, Floris A, Mathieu A, Cauli A. Demyelinating syndrome in SLE encompasses different subtypes: Do we need new classification criteria? Pooled results from systematic literature review and monocentric cohort analysis. Autoimmun Rev 2017 Mar;16(3):244-52.
  4. Birnbaum J, Petri M, Thompson R, Izbudak I, Kerr D. Distinct subtypes of myelitis in systemic lupus erythematosus. Arthritis Rheum 2009 Nov;60(11):3378-87.
  5. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol 2007 Sep;6(9):805-15.
  6. Petri M, Orbai A-M, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012 Aug;64(8):2677-86.
  7. Proposed diagnostic criteria and nosology of acute transverse myelitis | Neurology [Internet]. [cited 2020 Jul 7]. Available from: https://n.neurology.org/content/59/4/499.long
  8. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992 Jun;35(6):630-40.
  9. Fang W, Zheng Y, Yang F, Cai M-T, Shen C-H, Liu Z-R, et al. Short segment myelitis as the initial and only manifestation of aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorders. Ther Adv Neurol Disord 2020;13:1756286419898594.
  10. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015 Jul 14;85(2):177-89.
  11. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 Nov;33(11):1444-52.
  12. Kaplin AI, Krishnan C, Deshpande DM, Pardo CA, Kerr DA. Diagnosis and management of acute myelopathies. Neurologist 2005 Jan;11(1):2-18.
  13. Williams JN, Speyer CB, Kreps DJ, Kimbrough DJ, Costenbader K, Bhattacharyya S. Spinal cord syndromes in patients with systemic lupus erythematosus: differentiating lupus myelitis, neuromyelitis optica, and multiple sclerosis. Lupus 2019 Dec;28(14):1656-62.
  14. Mok CC, Lau CS, Chan EY, Wong RW. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment, and outcome. J Rheumatol 1998 Mar;25(3):467-73.
  15. Neuromyelitis optica spectrum disorders with and without connective tissue disorders | BMC Neurology | Full Text [Internet]. [cited 2020 Jul 7]. Available from: https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-018-1182-5
  16. Borowoy AM, Pope JE, Silverman E, Fortin PR, Pineau C, Smith CD, et al. Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. Semin Arthritis Rheum 2012 Oct;42(2):179-85.
  17. Bergamaschi R, Ghezzi A. Devic’s neuromyelitis optica: clinical features and prognostic factors. Neurol Sci 2004 Nov;25 Suppl 4:S364-367.
  18. Hryb JP, Chiganer E, Contentti EC, Di Pace JL, Lessa C, Perassolo MB. Myelitis in systemic lupus erythematosus: clinical features, immunological profile and magnetic resonance imaging of five cases. Spinal Cord Ser Cases 2016 Jul 7;2:16005.
  19. Kolfenbach JR, Horner BJ, Ferucci ED, West SG. Neuromyelitis optica spectrum disorder in patients with connective tissue disease and myelitis. Arthritis Care Res (Hoboken) 2011 Aug;63(8):1203-8.
  20. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007 Jan;13(1):128-32.
  21. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke K-D, Hellwig K, et al. Apheresis therapies for NMOSD attacks. Neurol Neuroimmunol Neuroinflamm [Internet] 2018 Sep 26 [cited 2020 Jul 7];5(6). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6192689/
  22. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998 Oct;51(4):1219-20.
  23. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017 Sep;264(9):2003-9.
  24. Chen H, Qiu W, Zhang Q, Wang J, Shi Z, Liu J, et al. Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. Eur J Neurol 2017;24(1):219-26.
  25. Damato V, Evoli A, Iorio R. Efficacy and Safety of Rituximab Therapy in Neuromyelitis Optica Spectrum Disorders: A Systematic Review and Meta-analysis. JAMA Neurol 2016 Nov 1;73(11):1342-8.
  26. Ciron J, Audoin B, Bourre B, Brassat D, Durand-Dubief F, Laplaud D, et al. Recommendations for the use of Rituximab in neuromyelitis optica spectrum disorders. Rev Neurol (Paris) 2018;174(4):255-64.
  27. Pittock SJ, Berthele A, Fujihara K, Kim HJ, Levy M, Palace J, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med 2019 15;381(7):614-25.
  28. Cree BAC, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk DM, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet 2019 12;394(10206):1352-63.
  29. Yang C-S, Zhang QX, Chang SH, Zhang LJ, Li LM, Qi Y, et al. Neuromyelitis optica spectrum disorders with and without connective tissue disorders. BMC Neurology 2018 Oct 24;18(1):177.